Mapi Pharma
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Weizmann Science Park 16, Ness Ziona, Ce...Phone Number
+972 737121213Website
www.mapi-pharma.comRevenue
$11.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Mapi Pharma
Mapi Pharma is a clinical stage pharmaceutical company focused on developing innovative long-acting depot injectable treatments and complex active pharmaceutical ingredients. Their lead product, Glatiramer Acetate Depot, is designed for the treatment of multiple sclerosis, targeting a significant market. The company is also developing other formulations, including Pregabalin ER for neuropathic pain and various treatments for schizophrenia. Founded in 2008 and based in Ness Ziona, Israel, Mapi Pharma operates fully integrated GMP manufacturing facilities.Explore more
Mapi Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mapi Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Mapi Pharma has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Mapi Pharma recently announced quarterly report
Check out if Mapi Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Mapi Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Mapi Pharma
Check if Mapi Pharma has recently received funding, and reach out quickly before it becomes old news!
Mapi Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Mapi Pharma had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Mapi Pharma
Find more new buyers
Company Profile Activity
Activity Insights
Mapi Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mapi Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mapi Pharma.
Mapi Pharma financials insights
Gather financial insights about Mapi Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Share Placement
$10M
Mapi Pharma Tech Stack
A closer look at the technologies used by Mapi Pharma
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Mapi Pharma News & Media
Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables
Company to present investment opportunity at SelectUSA Summit Company to present investment opportunity at SelectUSA SummitMapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) at AAN 2026
Poster scheduled for presentation on Tuesday, April 21, 8:00 AM - 9:00 AM CDT Poster scheduled for presentation on Tuesday, April 21, 8:00 AM - 9:00 AM CDTMapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET.Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present new safety and efficacy data from the GA Depot Phase II study in primary progressive multiple sclerosis (PPMS) at the ACTRIMS Forum 2026 Conference, to take place February 5-7, 2026, in San Diego, CA.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mapi Pharma
Sign Up For FreeTo access detailed company insights
Mapi Pharma is a clinical stage pharmaceutical company focused on developing innovative long-acting depot injectable treatments and complex active pharmaceutical ingredients. Their lead product, Glatiramer Acetate Depot, is designed for the treatment of multiple sclerosis, targeting a significant market. The company is also developing other formula... Read More
